Gataparsen
| Clinical data | |
|---|---|
| Other names | LY2181308 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Gataparsen (development code LY2181308) is an antisense oligonucleotide that complementarily binds to survivin mRNA and inhibits its expression in tumor tissue.[1]
It being investigated for a number of different cancers.[2]
It is targeted at survivin which prevents cells dying.[3]
Clinical trials[edit]
It has completed a phase II trial for acute myeloid leukemia.[4]
A phase II trial for non-small cell lung cancer has started.[5]
A phase II trial for hormone-refractory prostate cancer will run until early 2012.[6]
References[edit]
- ^ Tanioka M, Nokihara H, Yamamoto N, Yamada Y, Yamada K, Goto Y, et al. (August 2011). "Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors". Cancer Chemotherapy and Pharmacology. 68 (2): 505–11. doi:10.1007/s00280-010-1506-7. PMID 21079959.
- ^ "Search of: LY2181308". ClinicalTrials.gov.
- ^ "Cancer". Isis Pharmaceuticals. Archived from the original on 2009-10-10. Retrieved 2019-08-31.
- ^ "A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia". ClinicalTrials.gov.
- ^ "Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer". ClinicalTrials.gov.
- ^ "A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer". ClinicalTrials.gov.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |